SCHEMBL5863371

SCHEMBL5863371

CCOC(=O)c1ccnc(N2CCN(C(=O)OC(C)(C)C)CC2)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
GPR119 Q8TDV5 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ACHE P22303 1/20 0.45
TSHR P16473 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 2/20 0.45
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
TP53 P04637 1/20 0.44
IDE P14735 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29089138 0.87 POLB (0.56) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL5863376 0.86 ACHE (0.48) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL1580545 0.81 POLB (0.47) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL31167811 0.80 MEN1 (0.52) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL21854083 0.80 SMN1; SMN2 (0.45) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL1580191 0.79 ALDH1A1 (0.49) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL1522008 0.78 MEN1 (0.50) MAPTGPR119SMN1; SMN2ALDH1A1MEN1
SCHEMBL14598663 0.78 MEN1 (0.53) MAPTSMN1; SMN2ALDH1A1MEN1LMNA
SCHEMBL27620936 0.78 ACHE (0.53) MAPTGPR119MEN1KMT2AACHE
SCHEMBL14598744 0.78 GAA (0.59) MAPTGPR119SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC MAPT 4733/4885GPR119 245/4885SMN1; SMN2 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.